Contra-indicated in patients with severe renal impairment, end stage renal disease, or on dialysis.
- TRADE NAME: Steglatro (Merck Sharpe & Dohme)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
- HALF-LIFE: 17 hours
- FDA APPROVAL DATE: 12/19/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Not recommended during the second and third trimesters of pregnancy
- See adverse reactions attributed to class:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
Please login to view the rest of this drug profile.
Page last updated 01/23/2025
